00:52 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

RNA party

A study in Cell has uncovered a brain regulatory network involving a circular RNA, a long non-coding RNA and two microRNAs, and could provide some much needed insights in a field where finding links to...
08:00 , Mar 5, 2015 |  BC Innovations  |  Tools & Techniques

Nixing antibody aggregation

Australian newco Solvanix Pty. Ltd. was founded last month on the basis of two amino acid changes in an antibody. The start-up expanded its early studies showing the altered residues transformed a misbehaving mAb into...
07:00 , Sep 29, 2014 |  BioCentury  |  Emerging Company Profile

Ossianix: Shark teeth

Ossianix Inc. is developing small shark-derived single domain antibodies that could access hard to hit neuronal targets. The company is working with H. Lundbeck A/S to develop specific inhibitors of pain target P2X3 and to...
07:00 , Mar 14, 2013 |  BC Innovations  |  Cover Story

Squaring the RNA circle

Two European teams have provided the strongest evidence to date that circular RNAs are widely expressed in human cells and have clear regulatory functions. 1,2 The biomedical relevance of circular RNAs remains largely unexplored, but...
07:00 , Mar 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Cancer; neurology MicroRNA-7 (miR-7); cerebellar degeneration-related protein 1 antisense (ciRS-7; CDR1as) In silico and cell culture studies suggest inhibiting the circular RNA ciRS-7 upregulates miR-7...